Eight years younger in seven months. It is the kind of proposition that makes a supplement bottle sound like a time machine.
The number comes from a real scientific paper about a formulation containing calcium alpha-ketoglutarate, better known as Ca-AKG. The researchers reported a striking change in a DNA-based estimate of biological age. What they did not establish was that anyone gained eight years of life. [1]
That distinction is the central issue in evaluating Ca-AKG. There is enough science to take the compound seriously. There is not yet convincing clinical evidence that taking it makes people live longer or reverses aging throughout the body.
KEY TAKEAWAY
No study has shown that Ca-AKG helps people live longer. The eight-year drop in biological age came from a 2021 study of 42 people with no placebo group, and larger mouse trials found no lifespan gain. The first placebo-controlled human trial, ABLE, has not yet published its main results. Ca-AKG is a plausible candidate, not a proven anti-aging supplement.
What is Ca-AKG?
Alpha-ketoglutarate is already part of human biology, participating in the metabolic cycle that helps cells generate energy. It also supports enzymes involved in regulating chemical markings on DNA. Ca-AKG is its calcium salt. Those functions give researchers plausible reasons to investigate it, but a molecule having an essential job inside the body does not establish that taking extra will improve health. [2]
The distinction matters because a convincing explanation of how something might work can feel remarkably like evidence that it does.
What do the mouse studies show?
In 2020, researchers reported that Ca-AKG reduced frailty and extended lifespan in a mouse model. The possibility of reducing the period of poor health near the end of life was especially compelling. Living longer has more appeal when those additional days are good ones. [3]
But the animal evidence has become more complicated. A March 2026 paper from the National Institute on Aging’s Interventions Testing Program reported no lifespan extension from AKG in genetically diverse mice when treatment began at seven months. An earlier experiment starting at 18 months had also found no significant benefit. These experiments used different conditions from the original positive study; they are not a definitive verdict on every Ca-AKG formulation sold to humans. They do show why one successful animal experiment cannot settle the question. [4]
Where did “eight years younger” come from?
The widely cited human result arrived in 2021. Researchers retrospectively examined 42 people who had taken Rejuvant, a formulation containing Ca-AKG and vitamins, for an average of seven months. Their estimated biological age fell by roughly eight years.
There was no randomized placebo group. The formulation had multiple ingredients, preventing the study from isolating Ca-AKG’s contribution. The paper also disclosed commercial relationships, including an author’s role as a consultant and board member for the manufacturer.
Those limitations do not make the result worthless. They make it preliminary. Without an appropriate comparison group, the study cannot reliably separate the supplement’s effects from other changes, selection effects or measurement variability. Its result justified a better experiment, not a promise of eight birthdays refunded. [1]
What did the 2026 Aging Cell study find?
A larger paper published in Aging Cell in 2026 provided another intriguing signal. Researchers analyzed data from 4,260 people who had purchased saliva-based epigenetic tests and supplied lifestyle and supplement information. This was the whole study population, not 4,260 people assigned to take Ca-AKG.
The 143 users of a delayed-release Ca-AKG-and-vitamin formulation had an age estimate about 1.8 years lower than expected after accounting for chronological age. The association persisted after adjustment for several other factors. Ordinary AKG did not show a statistically significant association on that measure.
However, the study was observational. Participants chose their supplements, and the authors acknowledged recruitment and healthy-user biases. Dose and frequency were not reported. In the smaller longitudinal analysis, the apparent association did not remain statistically significant after multivariate correction.
The finding warrants investigation. It does not prove that delayed release caused the difference or that the product is clinically superior to competing supplements. [5]
The manufacturer’s May 2026 announcement framed that research as Rejuvant outperforming other supplements. Readers should recognize that this was the company’s interpretation of an observational study, not the outcome of a randomized competition among products. The company also stated that it had not sponsored, directed or controlled the research. [6]
The paper’s senior author, Brian Kennedy, was also an author of the 2021 Rejuvant study. In the company’s announcement, he said he had personally used the product for several years. [1] [6]
The commercial appeal is understandable. Years are easier to sell than uncertainty.
Does a younger biological age mean a longer life?
Biological-age tests aim to capture aspects of aging that a birth certificate cannot. Some use patterns of DNA methylation, chemical markings associated with age, to generate an estimate. They can be valuable research tools. But showing that an intervention moves a biomarker is different from validating that movement as a substitute for better health or longer survival. A scientific framework published in Cell lays out that distinction and the additional validation required. [7]
Consider the consumer’s actual questions: Will I remain independent longer? Will I avoid disease? Will I feel better? A lower number on a laboratory report is interesting precisely because it might help answer those questions. It cannot answer them by itself.
Is there other human evidence?
There is also human research beyond the aging clocks. A randomized, double-blind study published in 2007 examined 76 postmenopausal women with osteopenia over six months. Calcium-bound AKG improved a marker of bone breakdown compared with calcium alone. However, the difference in lumbar-spine bone density between groups was not statistically significant. This supports further investigation of a specific bone-related effect in a specific population; it does not establish general rejuvenation. [8]
What is the ABLE trial?
The ABLE trial in Singapore was designed to provide stronger evidence: 120 adults, sustained-release Ca-AKG or placebo, six months of treatment and three months of follow-up. Its planned assessments include DNA-based aging measures, strength, aerobic capacity and vascular measures. [2]
Published ABLE reports located for this article included a 2025 recruitment analysis and a September 25, 2026 paper about using activity monitors. These address how the trial was conducted; they do not establish its primary treatment benefit. As of this article’s research date, a peer-reviewed report of ABLE’s primary efficacy results was not located. [9] [10]
Is Ca-AKG safe?
Safety deserves the same precision. Being naturally present in the body does not establish that a supplement is safe at every dose or over years of use. The FDA does not approve dietary supplements for safety and effectiveness before they reach the market, although manufacturers are responsible for meeting applicable safety and labeling requirements. [11]
Ca-AKG also supplies calcium, and some products add vitamins. The full formulation therefore matters. Calcium can interact with certain medications, and total intake deserves attention, particularly when several supplements are combined. A clinician or pharmacist can evaluate the label against an individual’s medications and health history. Evidence about supplemental calcium generally should not be misrepresented as proof that Ca-AKG itself causes a particular harm. [12]
The verdict
The fair verdict is that Ca-AKG remains a plausible candidate awaiting convincing proof of meaningful anti-aging benefits in people. Calling it useless would dismiss research worth pursuing. Calling it proven would ask consumers to accept conclusions the studies have not earned.
The next breakthrough may come from this molecule. It may come from another. Either way, the standard should be whether people live better and longer.
A younger number is an interesting result. More healthy years would be the product worth buying.
See where your own numbers stand: take the Life Expectancy Calculator.
Frequently asked questions
What is Ca-AKG?
Ca-AKG is calcium alpha-ketoglutarate, the calcium salt of alpha-ketoglutarate, a molecule the body already makes. It takes part in the metabolic cycle that helps cells generate energy and supports enzymes that regulate chemical markings on DNA.
Does Ca-AKG reverse aging?
Not on current evidence. A 2021 study reported an eight-year drop in a DNA-based estimate of biological age, but it had no placebo group, tested a multi-ingredient product, and did not measure lifespan or health outcomes.
Does Ca-AKG extend lifespan?
It did in one 2020 mouse study. Later tests by the National Institute on Aging’s Interventions Testing Program found no lifespan extension in genetically diverse mice, whether treatment started at seven months or at 18 months. No human study has shown longer life.
What is the ABLE trial?
ABLE is a randomized, placebo-controlled trial in Singapore giving 120 adults sustained-release Ca-AKG or placebo for six months, with three months of follow-up. As of September 29, 2026, a peer-reviewed report of its primary efficacy results had not been located.
Is Ca-AKG safe to take?
Being naturally present in the body does not prove a supplement is safe at every dose or over years. The FDA does not approve supplements before sale. Ca-AKG also supplies calcium, which can interact with some medications, so a clinician or pharmacist should review the full label.
Sources
Research reviewed September 29, 2026.
- Demidenko et al. (2021). Rejuvant and DNA methylation age.
- Sandalova et al. (2023). ABLE intervention study protocol.
- Shahmirzadi et al. (2020). Ca-AKG, lifespan and frailty in mice.
- Korstanje et al. (2026). Interventions Testing Program lifespan findings.
- Pabis et al. (2026). Supplements and biological age in healthy individuals.
- Ponce De Leon Health (May 28, 2026). Manufacturer announcement.
- Biomarkers of Aging Consortium (2023). Evaluating longevity interventions.
- Filip et al. (2007). Ca-AKG and bone markers in women with osteopenia.
- Lim et al. (2025). ABLE recruitment evaluation.
- Lu et al. (September 25, 2026). ABLE activity-monitor implementation.
- US FDA. FDA 101: Dietary Supplements.
- NIH Office of Dietary Supplements. Calcium fact sheet.